Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MPGN II--genetically determined by defective complement regulation?

Christoph Licht, Ursula Schlötzer-Schrehardt, Michael Kirschfink

    Pediatric Nephrology (Berlin, Germany)
    |October 7, 2006
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Interleukin-17A mediates cardiorenal injury in oxalate nephropathy.

    Cardiovascular research·2026
    Same author

    Machine learning prediction of childhood nephrotic syndrome outcomes.

    Pediatric nephrology (Berlin, Germany)·2026
    Same author

    A Narrative Review of C3 Glomerulopathy: From Pathogenesis to Targeted Therapy.

    Canadian journal of kidney health and disease·2026
    Same author

    Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis.

    Clinical journal of the American Society of Nephrology : CJASN·2026
    Same author

    Development of an Exergaming-Intervention for Children and Adolescents During Hemodialysis: A Pilot Study.

    Studies in health technology and informatics·2026
    Same author

    Associations Between Toxic Metal Exposure and Childhood Nephrotic Syndrome.

    Kidney international reports·2026

    Membranoproliferative glomerulonephritis type II (MPGN II) involves complement system dysregulation. Identifying genetic factors and complement defects offers potential therapeutic strategies like plasma infusion for MPGN II.

    Area of Science:

    • Nephrology
    • Immunology
    • Genetics

    Background:

    • Membranoproliferative glomerulonephritis type II (MPGN II) is a rare kidney disease characterized by complement deposits in the glomerular basement membrane (GBM).
    • MPGN II leads to progressive renal dysfunction and end-stage renal disease due to GBM functional impairment.
    • Pathogenesis involves complement dysregulation, including C3 nephritic factor (C3NeF) and other genetically determined factors affecting complement control.

    Discussion:

    • Defective complement regulation in MPGN II can arise from various genetic factors beyond C3NeF.
    • Factor H deficiency, identified in animal models and patients, represents a significant cause of complement system activation in MPGN II.
    • Mutations in the Factor H gene, autoantibodies against Factor H or C3, and C3 mutations contribute to impaired complement regulation.

    Related Experiment Videos

    Key Insights:

    • MPGN II pathogenesis is linked to a dysregulated complement system, not solely C3NeF.
    • Factor H deficiency is a key factor in MPGN II, leading to uncontrolled complement activation.
    • Multiple genetic and autoimmune factors can disrupt complement regulation in MPGN II.

    Outlook:

    • Identifying specific complement defects in MPGN II patients is crucial for targeted therapies.
    • Plasma infusion may serve as a treatment to replace missing complement factors, potentially halting or slowing disease progression.
    • Further research into the genetic and autoimmune underpinnings of MPGN II can reveal novel therapeutic targets.